Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial

Michael Anstead; Sonya L. Heltshe; Umer Khan; Joseph T. Barbieri; Markus Langkamp; Gerd Döring; Shimoni Dharia; Ronald L. Gibson; Miriam M. Treggiari; James Lymp; Margaret Rosenfeld; Bonnie Ramsey

doi:10.1016/j.jcf.2012.08.001

Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial

Michael Anstead
, Sonya L. Heltshe
, Umer Khan
, Joseph T. Barbieri
, Markus Langkamp
, Gerd Döring
, Shimoni Dharia
, Ronald L. Gibson
, Miriam M. Treggiari
, James Lymp
, Margaret Rosenfeld
, Bonnie Ramsey

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Background: The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood. Methods: Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication. Results: Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60. week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation. Conclusion: P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.

Original language	English
Pages (from-to)	147-153
Number of pages	7
Journal	Journal of Cystic Fibrosis
Volume	12
Issue number	2
DOIs	https://doi.org/10.1016/j.jcf.2012.08.001
State	Published - Mar 2013

Bibliographical note

Funding Information:
This study was supported by CFFT RAMSEY10A0 and CFFT EPIC04K0 from the US Cystic Fibrosis Foundation and NIH P30 DK089507 , NIH U01 HL80310 , and NIH-R01 AI30162 from The National Institutes of Health .

Funding

This study was supported by CFFT RAMSEY10A0 and CFFT EPIC04K0 from the US Cystic Fibrosis Foundation and NIH P30 DK089507 , NIH U01 HL80310 , and NIH-R01 AI30162 from The National Institutes of Health .

Funders	Funder number
National Institutes of Health (NIH)	U01HL080310, P30DK089507
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases	R01AI030162
National Institute of Allergy and Infectious Diseases
Cystic Fibrosis Foundation Headquarters	NIH-R01 AI30162, P30 DK089507, U01 HL80310
Cystic Fibrosis Foundation Headquarters
Cystic Fibrosis Foundation Therapeutics Incorporated	EPIC04K0, RAMSEY10A0
Cystic Fibrosis Foundation Therapeutics Incorporated

Keywords

EPIC
Infection
Pseudomonas
Serology
Treatment

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.jcf.2012.08.001

Cite this

@article{37f6a035e91c4841ae964021e199eccb,

title = "Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial",

abstract = "Background: The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood. Methods: Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication. Results: Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60. week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation. Conclusion: P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.",

keywords = "EPIC, Infection, Pseudomonas, Serology, Treatment",

author = "Michael Anstead and Heltshe, \{Sonya L.\} and Umer Khan and Barbieri, \{Joseph T.\} and Markus Langkamp and Gerd D{\"o}ring and Shimoni Dharia and Gibson, \{Ronald L.\} and Treggiari, \{Miriam M.\} and James Lymp and Margaret Rosenfeld and Bonnie Ramsey",

note = "Funding Information: This study was supported by CFFT RAMSEY10A0 and CFFT EPIC04K0 from the US Cystic Fibrosis Foundation and NIH P30 DK089507 , NIH U01 HL80310 , and NIH-R01 AI30162 from The National Institutes of Health . ",

year = "2013",

month = mar,

doi = "10.1016/j.jcf.2012.08.001",

language = "English",

volume = "12",

pages = "147--153",

number = "2",

}

TY - JOUR

T1 - Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial

AU - Anstead, Michael

AU - Heltshe, Sonya L.

AU - Khan, Umer

AU - Barbieri, Joseph T.

AU - Langkamp, Markus

AU - Döring, Gerd

AU - Dharia, Shimoni

AU - Gibson, Ronald L.

AU - Treggiari, Miriam M.

AU - Lymp, James

AU - Rosenfeld, Margaret

AU - Ramsey, Bonnie

N1 - Funding Information: This study was supported by CFFT RAMSEY10A0 and CFFT EPIC04K0 from the US Cystic Fibrosis Foundation and NIH P30 DK089507 , NIH U01 HL80310 , and NIH-R01 AI30162 from The National Institutes of Health .

PY - 2013/3

Y1 - 2013/3

N2 - Background: The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood. Methods: Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication. Results: Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60. week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation. Conclusion: P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.

AB - Background: The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood. Methods: Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication. Results: Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60. week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation. Conclusion: P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.

KW - EPIC

KW - Infection

KW - Pseudomonas

KW - Serology

KW - Treatment

UR - https://www.scopus.com/pages/publications/84878014012

UR - https://www.scopus.com/pages/publications/84878014012#tab=citedBy

U2 - 10.1016/j.jcf.2012.08.001

DO - 10.1016/j.jcf.2012.08.001

M3 - Article

C2 - 22944725

AN - SCOPUS:84878014012

SN - 1569-1993

VL - 12

SP - 147

EP - 153

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - 2

ER -

Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this